Marc Beer has been the CEO and Chairman of Renovia since 2016 and in this time he has focused his efforts on addressing pelvic floor disorder, a condition that affects 250 million women in the world. For many years, the life-altering disorder did not have that many treatment options available. Even to this day, options are still rather limited which is something that Marc Beer and Renovia hope to be able to remedy so these women can live with less severe symptoms.
Renovia’s first product was approved by the Food and Drug Administration in the United States in April of 2018. The Leva device was funded through Marc Beer’s first round of capital raising for the company. With the second round of funding that was just recently completed in 2018, Marc Beer is expecting more products to reach the approval phase. The Series B round raised around $42 million for the company that has a strong focus on women’s health issues. There were investors from the first round who were impressed by the progress Renovia was able to make already and decided to put more of their capital into current and future products with the last round.
The device that was approved earlier in 2018 was designed to help train the muscles of the pelvic floor in order to strengthen them and give patients more control over their disorder. The device uses an interactive system that connects via Bluetooth with an app. Through the use of training, the product by Marc Beer’s Renovia was designed to improve the urinary incontinence issues that are very common among people with pelvic floor disorders. Marc Beer plans to release a new version of the state of the art device using some of the recently raised funding.
Aside from the new Leva device, there are 3 other products that Marc Beer’s company is currently working on that will be progressed using the most recent funding. These devices are being designed for not only therapeutic purposes like the Leva but also for diagnostic purposes as well. The company is happy with the amount of support that it has received through funding and belief in the vision that Marc Beer has for the company. Learn more: https://www.cnbc.com/video/2013/01/23/aegerion-ceo-on-promise-of-biopharma.html
Marc Beer has been an entrepreneur in different sectors of healthcare for more than 2 decades and has built quite a reputation over the years. Because of his leadership, his companies have been able to get many of their products approved by the FDA. The CEO and Chairman of Renovia also serves in the position of Chairman for Minerva Neuroscience as of 2013 and Good Start Genetics as of 2010.